The Cancer Immunotherapy Biomarker Testing Landscape.
* Context.--Cancer immunotherapy provides unprecedented rates of durable clinical benefit to late-stage cancer patients across many tumor types, but there remains a critical need for biomarkers to accurately predict clinical response. Although some cancer immunotherapy tests are associated with appr...
| Publicado en: | Archives of Pathology & Laboratory Medicine Vol. 144; no. 6; pp. 706 - 725 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | pictorial tables/charts Journal Article |
| Publicado: |
College of American Pathologists
Jun2020
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=143462121&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 143462121 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00039985 1FS jtl: Archives of Pathology & Laboratory Medicine issn: 00039985 maglogo: N pubinfo: dt: Jun2020 vid: 144 iid: 6 pid: 2550 pub: College of American Pathologists place: Northfield, Illinois artinfo: ui: 143462121 143462121 143462121 10.5858/arpa.2018-0584-CP 143462121 ppf: 706 ppct: 19 formats: fmt: @attributes: type: P tig: atl: The Cancer Immunotherapy Biomarker Testing Landscape. aug: au: Walk, Eric E. Yohe, Sophia L. Beckman, Amy Schade, Andrew Zutter, Mary M. Pfeifer, John Berry, Anna B. affil: Department of Medical & Scientific Affairs, Roche Tissue Diagnostics, Tucson, Arizona sug: subj: Immunotherapy Neoplasms Therapy Biological Markers Programmed Cell Death Ligand 1 Pathologic Processes Tumor Markers, Biological United States Food and Drug Administration ab: * Context.--Cancer immunotherapy provides unprecedented rates of durable clinical benefit to late-stage cancer patients across many tumor types, but there remains a critical need for biomarkers to accurately predict clinical response. Although some cancer immunotherapy tests are associated with approved therapies and considered validated, other biomarkers are still emerging and at various states of clinical and translational exploration. Objective.--To provide pathologists with a current and practical update on the evolving field of cancer immunotherapy testing. The scientific background, clinical data, and testing methodology for the following cancer immunotherapy biomarkers are reviewed: programmed death ligand-1 (PD-L1), mismatch repair, microsatellite instability, tumor mutational burden, polymerase d and e mutations, cancer neoantigens, tumor-infiltrating lymphocytes, transcriptional signatures of immune responsiveness, cancer immunotherapy resistance biomarkers, and the microbiome. Data Sources.--Selected scientific publications and clinical trial data representing the current field of cancer immunotherapy. Conclusions.--The cancer immunotherapy field, including the use of biomarker testing to predict patient response, is still in evolution. PD-L1, mismatch repair, and microsatellite instability testing are helping to guide the use of US Food and Drug Administration--approved therapies, but there remains a need for better predictors of response and resistance. Several categories of tumor and patient characteristics underlying immune responsiveness are emerging and may represent the next generation of cancer immunotherapy predictive biomarkers. Pathologists have important roles and responsibilities as the field of cancer immunotherapy continues to develop, including leadership of translational studies, exploration of novel biomarkers, and the accurate and timely implementation of newly approved and validated companion diagnostics. pubtype: Academic Journal doctype: pictorial tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|